Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Clinical Study for Inactivated Vaccine Against EV71

Trial Profile

A Clinical Study for Inactivated Vaccine Against EV71

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enterovirus A vaccine (Primary)
  • Indications Enterovirus A infections
  • Focus Adverse reactions
  • Sponsors Medigen Vaccine Biologics; Medigen Vaccinology Corp
  • Most Recent Events

    • 22 Feb 2019 Results assessing immunogenicity, safety, cross-reaction, and immune persistence of an inactivated enterovirus A71 vaccine, published in the Vaccine
    • 15 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 22 Mar 2017 Planned primary completion date changed from 1 Feb 2017 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top